Tracking Results of Ablations to Combat AF Registry Generation 2
NCT ID: NCT05111015
Last Updated: 2026-01-07
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
10000 participants
OBSERVATIONAL
2013-02-28
2030-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Combined Endoscopic Epicardial and Percutaneous Endocardial Ablation Versus Repeated Catheter Ablation in Persistent and Longstanding Persistent Atrial Fibrillation
NCT02695277
Dual Epicardial Endocardial Persistent Atrial Fibrillation(AF) Study (Staged DEEP)
NCT01661205
Atrial Fibrillation: Ablation or Surgical Treatment II: FAST II
NCT01336075
Thoracoscopic Ablation for Lone Atrial Fibrillation
NCT05708027
Thoracoscopic Surgical Versus Catheter Ablation Approaches for Primary Treatment of Persistent Atrial Fibrillation
NCT04715425
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
OTHER
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Open Concomitant Surgical Ablation Procedures
AtriCure's Open Concomitant Surgical Ablation Devices used for the management of Atrial Fibrillation.
Hybrid (Convergent) Ablation Procedures
AtriCure's Hybrid (Convergent) Ablation Devices used for the management of Atrial Fibrillation.
AtriCure Hybrid Totally Thoracoscopic Ablation Procedures
AtriCure's Hybrid Totally Thoracoscopic Surgical Ablation Devices used for the management of Atrial Fibrillation.
AtriCure LAA Exclusion Procedures
AtriCure's LAA Exclusion Devices used to exclude the Left Atrial Appendage for the management of Atrial Fibrillation.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient is willing to provide informed consent
3. Patient whose age is 18 years or above, or of legal age to give informed consent specific to state and national law
Exclusion Criteria
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
AtriCure, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Huntsville Hospital
Huntsville, Alabama, United States
St. Bernards Medical Center
Jonesboro, Arkansas, United States
CHI St. Vincent Heart Institute
Little Rock, Arkansas, United States
Loma Linda University Medical Center
Loma Linda, California, United States
Adventist Heart Institute (St. Helena Hospital)
St. Helena, California, United States
Valley View Hospital
Glenwood Springs, Colorado, United States
MedStar Washington Hospital
Washington D.C., District of Columbia, United States
Delray Medical Center
Delray Beach, Florida, United States
University of Florida
Gainesville, Florida, United States
Orlando Health Heart & Vascular Institute
Orlando, Florida, United States
St. Joseph's Hospital (BayCare)
Tampa, Florida, United States
Franciscan Health
Indianapolis, Indiana, United States
Kansas City Heart Rhythm Institute
Overland Park, Kansas, United States
Norton Heart & Vascular Institute
Louisville, Kentucky, United States
University of Michigan
Ann Arbor, Michigan, United States
Corewell Health
Grand Rapids, Michigan, United States
Washington University School of Medicine
St Louis, Missouri, United States
University of Nebraska Medical Center
Omaha, Nebraska, United States
Maimonides Health Heart & Vascular Institute
Brooklyn, New York, United States
Vassar Brothers Medical Center
Poughkeepsie, New York, United States
Atrium Health Wake Forest Baptist
Winston-Salem, North Carolina, United States
UH Cleveland Harrington Heart & Vascular Institute
Cleveland, Ohio, United States
Jackson Madison County General Hospital
Jackson, Tennessee, United States
Centennial Medical Center
Nashville, Tennessee, United States
Michael E. DeBakey VAMC - Houston
Houston, Texas, United States
Medical College of Wisconsin
Milwaukee, Wisconsin, United States
Nova Scotia Health Authority
Halifax, Nova Scotia, Canada
Waterloo Regional Health Network
Kitchener, Ontario, Canada
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Chris Minnerly
Role: primary
Erin Little
Role: primary
Related Links
Access external resources that provide additional context or updates about the study.
Related Info
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
TRAC-AF Registry
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.